Robert W. Baird Issues Positive Forecast for Beta Bionics (NASDAQ:BBNX) Stock Price

Beta Bionics (NASDAQ:BBNX) had its target price raised by equities researchers at Robert W. Baird from $14.00 to $16.00 in a report issued on Tuesday, Benzinga reports. The firm currently has a “neutral” rating on the stock. Robert W. Baird’s price objective would suggest a potential downside of 4.36% from the company’s current price.

Several other research firms also recently issued reports on BBNX. Bank of America cut their price objective on Beta Bionics from $23.00 to $11.00 and set a “neutral” rating on the stock in a report on Monday, May 18th. William Blair began coverage on shares of Beta Bionics in a research note on Friday, August 21st. They issued a “market perform” rating for the company. Weiss Ratings raised Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. Truist Financial boosted their price objective on shares of Beta Bionics from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Finally, Leerink Partners boosted their target price on Beta Bionics from $24.00 to $27.00 and gave the company an “outperform” rating in a report on Monday. Seven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $20.60.

Beta Bionics Stock Up 1.0%

NASDAQ BBNX opened at $16.73 on Tuesday. Beta Bionics has a 52 week low of $8.80 and a 52 week high of $32.71. The business’s fifty day simple moving average is $17.30 and its 200-day simple moving average is $13.82. The firm has a market cap of $752.68 million, a PE ratio of -10.14 and a beta of 3.37.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. The business had revenue of $32.01 million during the quarter. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. Research analysts expect that Beta Bionics will post -2.1 EPS for the current year.

Insider Buying and Selling

In other Beta Bionics news, CFO Stephen Feider sold 6,675 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total transaction of $127,559.25. Following the completion of the sale, the chief financial officer directly owned 159,378 shares of the company’s stock, valued at approximately $3,045,713.58. This trade represents a 4.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Steven Russell sold 4,221 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total value of $80,663.31. Following the sale, the insider directly owned 169,628 shares of the company’s stock, valued at $3,241,591.08. The trade was a 2.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 70,132 shares of company stock worth $1,284,623. Corporate insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in shares of Beta Bionics during the second quarter worth $52,340,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Beta Bionics in the 4th quarter valued at $40,437,000. Eversept Partners LP increased its stake in Beta Bionics by 108.6% in the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after buying an additional 736,576 shares during the period. 12 West Capital Management LP purchased a new position in Beta Bionics during the 4th quarter worth $17,520,000. Finally, Bruce & Co. Inc. purchased a new position in Beta Bionics during the 1st quarter worth $5,518,000.

Key Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: The FDA cleared Mint™, Beta Bionics’ reusable-and-disposable patch insulin pump. The device does not require recharging, supports leading continuous glucose monitors, and allows smartphone control, potentially expanding the company’s addressable market ahead of a planned 2027 launch. Beta Bionics Announces FDA Clearance of Mint
• Positive Sentiment: Beta Bionics and Senseonics announced plans to integrate Senseonics’ Eversense 365 one-year continuous glucose monitor with the iLet Bionic Pancreas, with a commercial launch targeted for the fourth quarter of 2026. The partnership could improve the iLet ecosystem and broaden its appeal to diabetes patients. Senseonics Announces Partnership with Beta Bionics
• Neutral Sentiment: The company also unveiled 3D Intelligence™, a next-generation insulin-dosing algorithm. While the technology may support future product development, its near-term financial impact remains uncertain.
• Negative Sentiment: Beta Bionics lowered its 2026 revenue guidance, raising concerns about near-term demand, execution, or commercialization momentum. The guidance reduction offsets some of the optimism from the Mint clearance. Beta Bionics Lowers 2026 Revenue Guidance
• Negative Sentiment: Several law firms announced or promoted a securities-fraud class action covering investors who purchased BBNX shares between July 30, 2025, and February 24, 2026. The complaints allege that Beta Bionics misled investors about the iLet’s safety, efficacy, commercial prospects, and handling of customer complaints. The allegations have not been proven, but the litigation creates legal, reputational, and potential financial risks; the lead-plaintiff deadline is November 3, 2026. BBNX Court Alert

Beta Bionics Company Profile

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.